GB1144915A - Improvements in or relating to pastille formulations - Google Patents

Improvements in or relating to pastille formulations

Info

Publication number
GB1144915A
GB1144915A GB5259967A GB5259967A GB1144915A GB 1144915 A GB1144915 A GB 1144915A GB 5259967 A GB5259967 A GB 5259967A GB 5259967 A GB5259967 A GB 5259967A GB 1144915 A GB1144915 A GB 1144915A
Authority
GB
United Kingdom
Prior art keywords
pastille
pastilles
nov
extract
parts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5259967A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Armour Pharmaceutical Co
Original Assignee
Armour Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armour Pharmaceutical Co filed Critical Armour Pharmaceutical Co
Priority to GB5259967A priority Critical patent/GB1144915A/en
Publication of GB1144915A publication Critical patent/GB1144915A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1,144,915. Pastilles. ARMOUR PHARMACEUTICAL CO. Ltd. and R. B. CHRISTIE. 23 Nov., 1967 [24 Nov., 1966], No. 52599/66. Heading A5B. A pharmaceutical pastille is composed of two parts which dissolve in the mouth at dissimilar rates. The two parts may be present as layers "side by side" or one may be present as a coating overlying the other. The pastilles may be employed as antitussives, when the more rapidly dissolved layer may comprise such substances as dextromethorphan, phenylpropanolamine, ephedrine HC1, pheniramine maleate, benzocaine, hyoscine HBr, isoprenaline sulphate, eucalyptus oil, menthol and thymol, and the more slowly dissolved layer may comprise NH 4 Cl, glycerol guaiacolate, syrup of tolu, extract of squill, extract of ipecacuanha, sodium benzoate, cresol, phenol, BiCO 3 , AI(OH) 3 , p-chlorophenol. The base may comprise sugar, glucose, gelatin and tartaric acid in varying proportions.
GB5259967A 1966-11-24 1966-11-24 Improvements in or relating to pastille formulations Expired GB1144915A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB5259967A GB1144915A (en) 1966-11-24 1966-11-24 Improvements in or relating to pastille formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5259967A GB1144915A (en) 1966-11-24 1966-11-24 Improvements in or relating to pastille formulations

Publications (1)

Publication Number Publication Date
GB1144915A true GB1144915A (en) 1969-03-12

Family

ID=10464542

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5259967A Expired GB1144915A (en) 1966-11-24 1966-11-24 Improvements in or relating to pastille formulations

Country Status (1)

Country Link
GB (1) GB1144915A (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0299211A1 (en) * 1987-06-24 1989-01-18 Bayer Ag DHP-coated tablet
EP0315332A1 (en) * 1987-10-27 1989-05-10 Richardson-Vicks, Inc. Antitussive liquid compositions containing phenol
DE3914170C1 (en) * 1989-04-28 1990-11-22 Capsoid Pharma Gmbh, 7128 Lauffen, De Pastille prepn. contg. vitamin(s) etc. - by dosing concave mould with liq. sol or gel mixt. contg. active ingredient, gelatin and water
DE4140192A1 (en) * 1991-12-05 1993-06-09 Alfatec-Pharma Gmbh, 6900 Heidelberg, De SOL-CONTROLLED THERMOCOLOID MATRIX ON GELATINE BASE FOR PERORAL RETARD FORMS
WO2000006127A1 (en) * 1998-07-30 2000-02-10 Warner-Lambert Company Centerfill delivery system for nutraceuticals
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
WO2002085334A1 (en) * 2001-04-25 2002-10-31 Pierre Fabre Medicament Medicinal tablet with prolonged release of the active principle
WO2003026627A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Composite dosage forms
US6616938B2 (en) 1994-05-02 2003-09-09 Josman Laboratories, Inc. Method of making chewing gum containing colloidal bismuth subcitrate
US6837696B2 (en) 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US6902738B2 (en) 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
GB2412865A (en) * 2004-04-07 2005-10-12 Atulkumar Sumanbhai Patel Cough mixture comprising ipecacuanha and guaifenesin
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7217381B2 (en) 2001-09-28 2007-05-15 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
DE102012221900A1 (en) 2012-11-29 2014-06-05 2LUTION GmbH Solid solution of caffeine and its derivative in a formulation material, useful as a dietary supplement, food or beverage or as a cosmetic agent, comprise a carrier material and solvent comprising glycerol and propylene glycol

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0299211A1 (en) * 1987-06-24 1989-01-18 Bayer Ag DHP-coated tablet
US4892741A (en) * 1987-06-24 1990-01-09 Bayer Aktiengesellschaft Press coated DHP tablets
EP0315332A1 (en) * 1987-10-27 1989-05-10 Richardson-Vicks, Inc. Antitussive liquid compositions containing phenol
DE3914170C1 (en) * 1989-04-28 1990-11-22 Capsoid Pharma Gmbh, 7128 Lauffen, De Pastille prepn. contg. vitamin(s) etc. - by dosing concave mould with liq. sol or gel mixt. contg. active ingredient, gelatin and water
DE4140192A1 (en) * 1991-12-05 1993-06-09 Alfatec-Pharma Gmbh, 6900 Heidelberg, De SOL-CONTROLLED THERMOCOLOID MATRIX ON GELATINE BASE FOR PERORAL RETARD FORMS
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6616938B2 (en) 1994-05-02 2003-09-09 Josman Laboratories, Inc. Method of making chewing gum containing colloidal bismuth subcitrate
US6902738B2 (en) 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
WO2000006127A1 (en) * 1998-07-30 2000-02-10 Warner-Lambert Company Centerfill delivery system for nutraceuticals
EP2184057A1 (en) * 2001-04-25 2010-05-12 Pierre Fabre Medicament Medicinal tablet with prolonged release of the active agent
WO2002085334A1 (en) * 2001-04-25 2002-10-31 Pierre Fabre Medicament Medicinal tablet with prolonged release of the active principle
FR2823974A1 (en) * 2001-04-25 2002-10-31 Pf Medicament SLOW RELEASE MEDICINAL LABEL FOR THE ACTIVE INGREDIENT
US8545870B2 (en) 2001-04-25 2013-10-01 Pierre Fabre Medicament Medicinal table with prolonged release of the active principle
EP2269588A1 (en) * 2001-04-25 2011-01-05 Pierre Fabre Medicament Medicinal tablet with prolonged release of the active agent
US7968120B2 (en) 2001-09-28 2011-06-28 Mcneil-Ppc, Inc. Modified release dosage forms
US8114328B2 (en) 2001-09-28 2012-02-14 Mcneil-Ppc, Inc. Method of coating a dosage form comprising a first medicant
US7217381B2 (en) 2001-09-28 2007-05-15 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US8673190B2 (en) 2001-09-28 2014-03-18 Mcneil-Ppc, Inc. Method for manufacturing dosage forms
WO2003026627A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Composite dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US6837696B2 (en) 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
EP1429742B1 (en) * 2001-09-28 2011-05-04 McNeil-PPC, Inc. Modified release dosage forms
EP1429742A2 (en) * 2001-09-28 2004-06-23 McNEIL-PPC, INC. Modified release dosage forms
US7972624B2 (en) 2001-09-28 2011-07-05 Shun-Por Li Method of manufacturing modified release dosage forms
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US8545887B2 (en) 2001-09-28 2013-10-01 Mcneil-Ppc, Inc. Modified release dosage forms
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
GB2412865A (en) * 2004-04-07 2005-10-12 Atulkumar Sumanbhai Patel Cough mixture comprising ipecacuanha and guaifenesin
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
DE102012221900A1 (en) 2012-11-29 2014-06-05 2LUTION GmbH Solid solution of caffeine and its derivative in a formulation material, useful as a dietary supplement, food or beverage or as a cosmetic agent, comprise a carrier material and solvent comprising glycerol and propylene glycol

Similar Documents

Publication Publication Date Title
GB1144915A (en) Improvements in or relating to pastille formulations
Hillyard et al. Antacid and antiulcer properties of the polysaccharide chitosan in the rat
Langemark et al. Effervescent ASA versus solid ASA in the treatment of tension headache. A double‐blind, placebo controlled study
CA2007260A1 (en) Effervescent analgesic antacid composition having reduced sodium content (ms-1569-cip-11)
GB1319103A (en) Alpha,beta-poly aspartic acid-hydroxy-alkylamides
WO1988002993A1 (en) Process for producing effervescent granulates, effervescent granulates thus produced and their use
EP1587498A1 (en) Powder pharmaceutical compositions
EP0579155B1 (en) Aqueous preparation of azulene sodium sulfonate
CA1070243A (en) Stable acetylsalicylic acid and phenylpropanolamine salt composition
GB1178294A (en) Improvements in or relating to Tableting Lubricants.
EP0140203A3 (en) Pharmaceutical preparation
IE32432L (en) Formulations containing alkoxybenzamide
GB1084864A (en) Medicated lozenges
György et al. The interaction of hemicholinium-3 and oxotremorine in isolated organ preparations
DE2135259A1 (en)
IE34077B1 (en) Dentifrice compositions
GB1354263A (en) Therapeutic composition
JPS56139415A (en) External analgesic agent for dental use
Harrisson et al. A comparative in Vivo study of antacids II
GB810537A (en) Sweetening composition
GB1173457A (en) Pharmaceutical Preparation for the Treatment of Coughs
GB1336609A (en) Antismoking preparation
Martinez et al. Effects of monensin on fluid and electrolyte secretion by the isolated, perfused rat submandibular gland
Thompson et al. The Effect of Alkali on the Absorption of a Peptide of Thyroxine from the Gastro-Intestinal Tract
GB1287433A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee